Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRAP1 | Q12931 | 1/20 | 0.51 |
| ▸ | IDO1 | P14902 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 4/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 4/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.46 |
| ▸ | HTT | P42858 | 2/20 | 0.46 |
| ▸ | PGR | P06401 | 1/20 | 0.46 |
| ▸ | MAOA | P21397 | 1/20 | 0.46 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.46 |
| ▸ | AVPR2 | P30518 | 1/20 | 0.46 |
| ▸ | HTR2B | P41595 | 1/20 | 0.46 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.46 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5731336 | 0.84 | TDP1 (0.43) | TRAP1IDO1MAPTTDP1ALDH1A1 | |
| SCHEMBL5731410 | 0.84 | SRD5A2 (0.46) | TRAP1IDO1MAPTTDP1ALDH1A1 | |
| Bromide SCHEMBL27886796 | 0.84 | TEK (0.50) | TRAP1IDO1MAPTTDP1ALDH1A1 | |
| SCHEMBL5710694 | 0.82 | FFAR1 (0.46) | TRAP1IDO1MAPTTDP1LMNA | |
| SCHEMBL16067092 | 0.81 | TBXAS1 (0.68) | TRAP1IDO1MAPTTDP1ALDH1A1 | |
| SCHEMBL3040732 | 0.81 | TBXAS1 (0.50) | MAPTTDP1ALDH1A1LMNACYP2C9 | |
| SCHEMBL5731206 | 0.81 | MRGPRX4 (0.49) | TP53RAB9ASMN1; SMN2 | |
| SCHEMBL5732276 | 0.81 | FABP4 (0.41) | TRAP1IDO1MAPTTDP1ALDH1A1 | |
| SCHEMBL19838966 | 0.80 | TRAP1 (0.68) | TRAP1IDO1MAPTTDP1ALDH1A1 | |
| SCHEMBL19838894 | 0.80 | TRAP1 (0.68) | TRAP1IDO1MAPTTDP1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110950749-B | IDO inhibitor and preparation method and application thereof | 中国科学院广州生物医药与健康研究院 | 2023-07-25 | — | — | CN | disclosed |
| EP-0864648-B1 | METHOD FOR SCREENING COMPOUNDS REGULATING THE EXPRESSION OF HUMAN-INDUCIBLE NITRIC OXIDE SYNTHASE | DAIICHI ASUBIO PHARMA CO LTD (JP) | 2006-11-29 | — | — | EP | disclosed |
| EP-1008346-B1 | NF-kB INHIBITORS CONTAINING BENZOQUINONE DERIVATIVES | DAIICHI ASUBIO PHARMA CO LTD (JP) | 2006-02-15 | — | — | EP | disclosed |
| US-6943196-B1 | NF-κB inhibitor comprising phenylmethyl benzoquinone as the active ingredient | DAIICHI SUNTORY PHARMA CO., LTD. (JP) | 2005-09-13 | — | — | US | disclosed |
| US-6703421-B1 | ADMINISTERING NF-KAPPA B INHIBITOR | DAIICHI SUNTORY PHARMA CO., LTD. (JP) | 2004-03-09 | — | — | US | disclosed |
| US-20040030129-A1 | NF-kappaB inhibitor comprising phenylmethyl benzoquinone as an active ingredient | DAIICHI ASUBIO PHARMA CO., LTD. (JP) | 2004-02-12 | — | — | US | disclosed |
| EP-1132093-A1 | PREVENTIVES OR REMEDIES FOR MYOCARDITIS, DILATED CARDIOMYOPATHY AND CARDIAC INSUFFICIENCY CONTAINING NF-KAPPA B INHIBITORS AS THE ACTIVE INGREDIENT | SUNTORY LIMITED (JP) | 2001-09-12 | — | — | EP | disclosed |
| US-6203982-B1 | DNA OF A 3' FLANKING REGION OF SYNTHASE GENE; DRUG SCREENING; ANTITUMOR/ANTICARCINOGENIC AGENTS; VIRICIDES; ANTIARTHRITIC AGENTS; ANTIISCHEMIC AGENTS; PREVENTION OF RESTENOSIS; TREATMENT OF AUTOIMMUNE DISEASE | SUNTORY LIMITED (JP) | 2001-03-20 | — | — | US | disclosed |
| EP-1008346-A1 | NF-$g(k)B INHIBITORS CONTAINING AS THE ACTIVE INGREDIENT PHENYLMETHYL BENZOQUINONE | SUNTORY LIMITED (JP) | 2000-06-14 | — | — | EP | disclosed |
| EP-0864648-A1 | METHOD FOR SCREENING COMPOUNDS REGULATING THE EXPRESSION OF HUMAN-INDUCIBLE NITRIC OXIDE SYNTHASE | SUNTORY LIMITED (JP) | 1998-09-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040030129-A1 | NF-kappaB inhibitor comprising phenylmethyl benzoquinone as an active ingredient | NFKBIA, NFKB2, NFKB1 | TRAP1 4020/4885IDO1 3927/4885MAPT 3958/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.